Graphic: 7 Biosimilars OK’d by FDA

The U.S. Food and Drug Administration to date has approved seven biosimilars, including Zarxio, Inflectra and Erelzi.

A rundown on the seven biosimilars can be seen at left.

(Graphic courtesy of Center for Biosimilars)

You might also be interested in:

Gottlieb’s Statement on Administration Funding Request February 19, 2018
Some Top Quotes From National Policy and Advocacy Summit on… April 30, 2018
Gottlieb’s Full Statement on New FDA Efforts to Prop… June 14, 2018
FDA Green Lights First Epoetin Alfa Biosimilar for Anemia May 16, 2018
How Will the FDA’s Payer Communications Guidance Affect… July 18, 2018
FDA Finalizes Communications Guidances June 16, 2018
Health Economist Issues Warning on Biosimilar Savings March 7, 2018